Follow
David Spriggs
David Spriggs
Massachusetts General Hospital
Verified email at MGH.HARVARD.EDU
Title
Cited by
Cited by
Year
Detection of circulating tumor necrosis factor after endotoxin administration
HR Michie, KR Manogue, DR Spriggs, A Revhaug, S O'Dwyer, ...
New England Journal of Medicine 318 (23), 1481-1486, 1988
22171988
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ...
Journal of Clinical Oncology 20 (12), 2824-2831, 2002
8092002
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ...
Clinical cancer research 8 (8), 2505-2511, 2002
6112002
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation.
DE Hallahan, DR Spriggs, MA Beckett, DW Kufe, RR Weichselbaum
Proceedings of the National Academy of Sciences 86 (24), 10104-10107, 1989
5521989
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.
HR Michie, DR Spriggs, KR Manogue, ML Sherman, A Revhaug, ...
Surgery 104 (2), 280-286, 1988
4901988
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
M Koneru, TJ Purdon, D Spriggs, S Koneru, RJ Brentjens
Oncoimmunology 4 (3), e994446, 2015
4212015
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
DR Spriggs, ML Sherman, H Michie, KA Arthur, K Imamura, D Wilmore, ...
JNCI: Journal of the National Cancer Institute 80 (13), 1039-1044, 1988
4111988
Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha.
DB Dubravec, DR Spriggs, JA Mannick, ML Rodrick
Proceedings of the National Academy of Sciences 87 (17), 6758-6761, 1990
4011990
BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II)
A Husain, G He, ES Venkatraman, DR Spriggs
Cancer research 58 (6), 1120-1123, 1998
3841998
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
OO Yeku, TJ Purdon, M Koneru, D Spriggs, RJ Brentjens
Scientific reports 7 (1), 10541, 2017
3642017
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ...
Clinical cancer research 18 (23), 6497-6508, 2012
3172012
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ...
Journal of Clinical Oncology 15 (1), 187-192, 1997
3091997
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
M Koneru, R O’Cearbhaill, S Pendharkar, DR Spriggs, RJ Brentjens
Journal of translational medicine 13, 1-11, 2015
3062015
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
ML Sherman, DR Spriggs, KA Arthur, K Imamura, E Frei 3rd, DW Kufe
Journal of Clinical Oncology 6 (2), 344-350, 1988
2911988
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial
RT Schooley, TC Merigan, P Gaut, MS Hirsch, M Holodniy, T Flynn, S Liu, ...
Annals of Internal Medicine 112 (4), 247-253, 1990
2741990
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
AC Lockhart, ML Rothenberg, J Dupont, W Cooper, P Chevalier, ...
Journal of Clinical Oncology 28 (2), 207, 2010
2692010
Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans
KA Bauer, H ten Cate, S Barzegar, DR Spriggs, ML Sherman, ...
2491989
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
X Zang, PS Sullivan, RA Soslow, R Waitz, VE Reuter, A Wilton, HT Thaler, ...
Modern pathology 23 (8), 1104-1112, 2010
2482010
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
RA Soslow, G Han, KJ Park, K Garg, N Olvera, DR Spriggs, ND Kauff, ...
Modern pathology 25 (4), 625-636, 2012
2452012
Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study
ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ...
Gynecologic oncology 112 (3), 563-567, 2009
2452009
The system can't perform the operation now. Try again later.
Articles 1–20